explore -WSS

explore

author：hotspot 2025-09-27 21:44:58 - browse：453

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Live blog: Hearing on CRISPR

WSS

Gene therapy’s promise and the high cost of hope

Indian pharmaceutical industry in denial over drug

Inari Medical to buy amputation prevention company LimFlow

Judge rejects Trump's request to move Stormy Daniels hush

Prime Medicine says its gene editing passes test in monkeys

Brain injuries and the importance of a second opinion

leisure time

explore

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

Trump demands the U.S. pay no more for drugs than other countries … again

I learned firsthand about improving diversity in clinical trials

Medical records are filled with copy

After Sarepta trial failure, Duchenne families brace for more debate

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Anesthesiologist group: stop taking Ozempic before surgery

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

focus

7 more heat

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

I learned firsthand about improving diversity in clinical trials

All of Us, NIH's precision medicine initiative, gets a big boost

Humans aren't the only ones with an imagination. Rats have it too

Stanford president faces new allegations over 1999 paper

hotspot

entertainment

focus

hotspot